MBX Biosciences elects Tiba Aynechi and Kent Hawryluk as Class I directors; Carl Gordon departs board

MBX Biosciences, Inc.

Stockholders elected Tiba Aynechi (24.3M for) and P. Kent Hawryluk (24.4M for) to three-year terms ending 2028.
Carl L. Gordon, Ph.D., CFA departed the board effective June 5, 2025; his term ended at the annual meeting.
Ratification of Ernst & Young as independent auditor for FY2025 passed with 27.8M for, 3,467 against.
Annual meeting held June 5, 2025; 33.4M shares outstanding as of April 11 record date.

item 5.02item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Carl L. Gordon

Director

MBX · MBX Biosciences, Inc.

Effective: 2025-06-05
Filed: Jun 06, 2025 23:59 UTC

Also effective as of June 5, 2025 was the departure of Carl L. Gordon, Ph.D., CFA from the Company's board of directors.

Source: SEC EDGAR

accession 0000950170-25-082697

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.